BusinessFibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic CancerBy Nasdaq OMXJun 22, 2017, 2:10 AM UTC
BusinessFibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with ChemotherapyBy Nasdaq OMXFeb 3, 2017, 4:06 PM UTC
BusinessPamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers SymposiumBy Nasdaq OMXJan 20, 2017, 10:06 PM UTC
BusinessFibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary FibrosisBy Nasdaq OMXMar 11, 2016, 1:00 PM UTC
BusinessFibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXJan 6, 2016, 10:47 PM UTC
